{"id":"NCT02285114","sponsor":"Gilead Sciences","briefTitle":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","officialTitle":"A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-01-20","primaryCompletion":"2019-11-04","completion":"2024-12-11","firstPosted":"2014-11-06","resultsPosted":"2021-01-12","lastUpdate":"2025-06-27"},"enrollment":41,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1"],"interventions":[{"type":"DRUG","name":"F/TAF","otherNames":[]},{"type":"DRUG","name":"3rd ARV agent","otherNames":[]},{"type":"DRUG","name":"Boosted PIs","otherNames":[]}],"arms":[{"label":"F/TAF+3rd ARV Agent (Cohort 1)","type":"EXPERIMENTAL"},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part A - Group 1)","type":"EXPERIMENTAL"},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part A - Group 2)","type":"EXPERIMENTAL"},{"label":"FTC/TAF+3rd ARV Agent (Cohort 3, Part A)","type":"EXPERIMENTAL"},{"label":"FTC/TAF+3rd ARV Agent (Cohort 4, Part A)","type":"EXPERIMENTAL"},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part B - Group 1)","type":"EXPERIMENTAL"},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part B - Group 2)","type":"EXPERIMENTAL"},{"label":"FTC/TAF+3rd ARV Agent (Cohort 3, Part B)","type":"EXPERIMENTAL"},{"label":"FTC/TAF+3rd ARV Agent (Cohort 4, Part B)","type":"EXPERIMENTAL"},{"label":"FTC/TAF+3rd ARV Agent (Extension Phase)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to confirm the TAF dose and to evaluate the pharmacokinetics (PK) of TAF, safety, and tolerability of F/TAF in children and adolescents with HIV-1 who are virologically suppressed (defined as having \\< 50 copies/mL of HIV-1 ribonucleic acid (RNA) for a period of at least 6 months) while on a stable 2 NRTI containing regimen.","primaryOutcome":{"measure":"Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF)","timeFrame":"Any time at Week 2 visit","effectByArm":[{"arm":"F/TAF 200/10 mg+3rd ARV Agent (Cohort 1)","deltaMin":139.9,"sd":113.23},{"arm":"F/TAF 200/25 mg+3rd ARV Agent (Cohort 1)","deltaMin":200.6,"sd":83.8}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":8,"countries":["United States","Panama","South Africa"]},"refs":{"pmids":[],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=GS-US-311-1269"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":28},"commonTop":["Nasopharyngitis","Headache","Influenza","Acne","Vomiting"]}}